Yazar "Demirci, U." seçeneğine göre listele
Listeleniyor 1 - 5 / 5
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey(Elsevier Science Inc, 2018) Kilickap, S.; Ozturk, A.; Karadurmus, N.; Korkmaz, T.; Yumuk, P.; Cicin, I.; Paydas, S.; Cilbir, E.; Sakalar, T.; Uysal, M.; Uskent, N.; Demir, N.; Sakin, A.; Turhal, N.; Keskin, S.; Tural, D.; Eralp, Y.; Basal, F.; Yasar, H.; Sendur, M. A.; Demirci, U.; Cubukcu, E.; Karaagac, M.; Karaca, S.; Tatli, A.; Yetisyigit, T.; Urvay, S.; Gursoy, P.; Uluc, B. Oyan; Turna, Z.; Kucukoner, M.; Olmez, O.; Cabuk, D.; Seker, M.; Unal, O.; Meydan, N.; Okutur, S.; Tunali, D.Öğe The effect of primary surgery in patients with stage IV breast cancer with bone metastasis only (protocol bomet MF14-01); a multi-center, registry study(Churchill Livingstone, 2021) Soran, A.; Dogan, L.; Ozbas, S.; Isik, A.; Trablus, D.; Demirci, U.; Dogan, M.[No Abstract Available]Öğe GLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC Patients [Meeting Abstract](Elsevier Science Inc, 2021) Peled, N.; Gillis, R.; Kilickap, S.; Froesch, P.; Orlov, S.; Filippova, E.; Demirci, U.[No Abstract Available]Öğe Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?(Oxford Univ Press, 2019) Kilickap, S.; Basal, F. Bugdayci; Demirkazik, A.; Gursoy, P.; Demirci, U.; Erman, M.; Korkmaz, T.[No abstract available]Öğe Microfluidic cell culture alters the behavior of cancer cell by mimicking dynamic tumor microenvironment(Wiley-Blackwell, 2016) Baskin, Y.; Kocal, G. Calibasi; Yildirim, N.; Guven, S.; Demirci, U.